IOVS Molecular Pharmacology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:3186-3193.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.02-1092
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rakic, J.-M.
Right arrow Articles by Munaut, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rakic, J.-M.
Right arrow Articles by Munaut, C.

Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization

Jean-Marie Rakic,1 Vincent Lambert,2 Laetitia Devy,2 Aernout Luttun,3 Peter Carmeliet,3 Carel Claes,4 Laurent Nguyen,5 Jean-Michel Foidart,2 Agnès Noël,2 and Carine Munaut2

1From the Department of Ophthalmology, University Hospital, Sart-Tilman, Liège, Belgium; the 2Laboratory of Tumor and Development Biology and the 5Center for Cellular and Molecular Neurobiology, University of Liège, Liège, Belgium; the 3Center for Transgene Technology and Gene Therapy, Katholieke Universiteit Leuven, Leuven, Belgium; and the 4Department of Ophthalmology, Middelheim Hospital, Antwerpen, Belgium.

PURPOSE. VEGF has been shown to be necessary, but not sufficient alone, for the development of subretinal pathologic angiogenesis. In the current study, the influence of placental growth factor (PlGF), a member of the VEGF family, in human and experimental choroidal neovascularization (CNV) was investigated.

METHODS. The presence of VEGF family member mRNA was evaluated by RT-PCR in neovascular membranes extracted during surgery. The spatial and temporal pattern of VEGF isoforms and PlGF mRNA expression were explored by using the laser capture catapulting technique and RT-PCR in a murine laser-induced model and in vitro. PlGF expression was also studied in human donor eyes. The influence of endogenous PlGF was evaluated in deficient mice (PlGF-/-) and by antibody-mediated neutralization of the PlGF receptor.

RESULTS. Human neovascular membranes consistently expressed VEGF-A, -B, and -C; PlGF; and VEGFR-1 and -2. The VEGF120 isoform mRNA was primarily induced in early stages of angiogenesis in vivo and in vitro. PlGF mRNA expression was present in the intact choroid and significantly upregulated during the course of experimental CNV. Both deficient PlGF expression in PlGF-/- mice and PlGF receptor neutralization in wild-type mice prevented the development of choroidal neovascularization induced by laser.

CONCLUSIONS. These observations demonstrate the participation of PlGF in experimental CNV. They identify therefore PlGF as an additional promising target for ocular antiangiogenic strategies.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
M. Jost, C. Maillard, J. Lecomte, V. Lambert, M. Tjwa, P. Blaise, M.-L. Alvarez Gonzalez, K. Bajou, S. Blacher, P. Motte, et al.
Tumoral and Choroidal Vascularization: Differential Cellular Mechanisms Involving Plasminogen Activator Inhibitor Type I
Am. J. Pathol., October 1, 2007; 171(4): 1369 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Koto, N. Nagai, H. Mochimaru, T. Kurihara, K. Izumi-Nagai, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, et al.
Eicosapentaenoic Acid Is Anti-Inflammatory in Preventing Choroidal Neovascularization in Mice
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4328 - 4334.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
R B Bhisitkul
Vascular endothelial growth factor biology: clinical implications for ocular treatments.
Br. J. Ophthalmol., December 1, 2006; 90(12): 1542 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Rosenfeld, D. M. Brown, J. S. Heier, D. S. Boyer, P. K. Kaiser, C. Y. Chung, R. Y. Kim, and the MARINA Study Group
Ranibizumab for Neovascular Age-Related Macular Degeneration
N. Engl. J. Med., October 5, 2006; 355(14): 1419 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. R. Lijnen, V. Christiaens, I. Scroyen, G. Voros, M. Tjwa, P. Carmeliet, and D. Collen
Impaired adipose tissue development in mice with inactivation of placental growth factor function.
Diabetes, October 1, 2006; 55(10): 2698 - 2704.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
B Zhao, A Ma, J Cai, and M Boulton
VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells
Br. J. Ophthalmol., August 1, 2006; 90(8): 1052 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. S. Lakka, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, V. H. Rao, C. Sioka, and J. S. Rao
Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas
J. Biol. Chem., June 10, 2005; 280(23): 21882 - 21892.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu
A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics
Cancer Res., May 15, 2004; 64(10): 3365 - 3370.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association for Research in Vision and Ophthalmology